Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Aged Fragile mRCC
NCT04134390Phase 2Completed
- Sponsor
- SOGUG
- Start
- Feb 2020
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in metastatic renal cell carcinoma (mRCC), sponsored by SOGUG. Primary endpoint: Objective Response Rate at 24 months. Started Feb 2020; status: completed.
02
Drugs
cabozantinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT04134390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04134390.